Delphine Denoyer1, Nathalie Perek, Nathalie Le Jeune, Jérôme Cornillon, Francis Dubois. 1. Department of Biophysics and Radiopharmaceuticals, Cell Survival and Adhesion Research Group, Jacques Lisfranc Faculty of Medicine, University of Saint-Etienne, 5 rue Ambroise Paré, 42023, Saint-Etienne, France. delphine.denoyer@univ-st-etienne.fr
Abstract
PURPOSE: Although a number of prognostic indicators have been developed, it is still difficult to predict the biological behaviour of all cancer types.( 99m)Tc-(V)-DMSA (V DMSA) uptake and focal adhesion kinase (FAK) expression and activation level could be potential agents for this purpose. We hypothesised the existence of a correlation between V DMSA, whose uptake is linked to phosphate ions, essential compounds for tumour growth and cell proliferation, and the adhesion protein FAK, whose elevated expression and level of constitutive activation are implicated in cancer progression. The aim of this study was to assess the relationship between V DMSA incorporation rate and FAK expression and activation by phosphorylation on tyrosine 397 residue. METHODS: We determined V DMSA uptake in six different cancer cell lines and we measured FAK expression and activation by using Western Blotting analysis. Correlations with factors known to be associated with poor prognosis, such as invasive potential, resistance to chemotherapy and proliferation rate, were also investigated. RESULTS: The cell lines exhibited different V DMSA incorporation rates. In addition, these cells showed the same FAK expression, but various degrees of activation. A correlation was observed between V DMSA uptake and level of FAK phosphorylation and between V DMSA or constitutive FAK activation and proliferation rate. However, no correlation was shown between these parameters and the other factors tested, i.e. invasive potential and anticancer drug resistance. CONCLUSION: The results of this in vitro study clearly demonstrate that phosphorylation of FAK, proliferation rate and V DMSA uptake are closely related. Because proliferation and a high level of constitutive FAK activation are linked to cancer progression, it can be assumed that in vivo V DMSA uptake reflects tumour aggressiveness.
PURPOSE: Although a number of prognostic indicators have been developed, it is still difficult to predict the biological behaviour of all cancer types.( 99m)Tc-(V)-DMSA (V DMSA) uptake and focal adhesion kinase (FAK) expression and activation level could be potential agents for this purpose. We hypothesised the existence of a correlation between V DMSA, whose uptake is linked to phosphate ions, essential compounds for tumour growth and cell proliferation, and the adhesion protein FAK, whose elevated expression and level of constitutive activation are implicated in cancer progression. The aim of this study was to assess the relationship between V DMSA incorporation rate and FAK expression and activation by phosphorylation on tyrosine 397 residue. METHODS: We determined V DMSA uptake in six different cancer cell lines and we measured FAK expression and activation by using Western Blotting analysis. Correlations with factors known to be associated with poor prognosis, such as invasive potential, resistance to chemotherapy and proliferation rate, were also investigated. RESULTS: The cell lines exhibited different V DMSA incorporation rates. In addition, these cells showed the same FAK expression, but various degrees of activation. A correlation was observed between V DMSA uptake and level of FAK phosphorylation and between V DMSA or constitutive FAK activation and proliferation rate. However, no correlation was shown between these parameters and the other factors tested, i.e. invasive potential and anticancer drug resistance. CONCLUSION: The results of this in vitro study clearly demonstrate that phosphorylation of FAK, proliferation rate and V DMSA uptake are closely related. Because proliferation and a high level of constitutive FAK activation are linked to cancer progression, it can be assumed that in vivo V DMSA uptake reflects tumour aggressiveness.
Authors: P Beauchesne; S Bertrand; M J N'guyen; T Christianson; J F Dore; F Mornex; J A Bonner Journal: Cancer Chemother Pharmacol Date: 1998 Impact factor: 3.333
Authors: Mark S Duxbury; Hiromichi Ito; Eric Benoit; Michael J Zinner; Stanley W Ashley; Edward E Whang Journal: Biochem Biophys Res Commun Date: 2003-11-21 Impact factor: 3.575
Authors: Andreas D Fotopoulos; George A Alexiou; Ann Goussia; Athanasios Papadopoulos; Athanasios P Kyritsis; Konstantinos S Polyzoidis; Spyridon Voulgaris; Spyridon Tsiouris Journal: J Neurooncol Date: 2008-05-06 Impact factor: 4.130
Authors: Vassilios J Papantoniou; Evangelia K Sotiropoulou; Pipitsa N Valsamaki; Angeliki G Tsaroucha; Maria G Sotiropoulou; Nikolaos D Ptohis; Aikaterini J Stipsanelli; Konstantinos E Dimitrakakis; Spyridon G Marinopoulos; Spyridon T Tsiouris; Aris J Antsaklis Journal: J Med Case Rep Date: 2010-03-17